SEC Can't Prove Stock Buyback Scheme, GSK Unit Says
The U.S. Securities and Exchange Commission hasn't identified evidence that Stiefel Laboratories Inc. and its former CEO defrauded investors and employees by repurchasing stock at dramatically undervalued prices before a $2.9...To view the full article, register now.
Already a subscriber? Click here to view full article